Press Releases

Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up. KEYNOTE-001 Findings Show Continued Benefit in Response...

Kyowa Hakko Kirin Co Ltd announced that AstraZeneca obtained the positive top-line results that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary end-point in two pivotal Phase III registrational trials (SIROCCO...

Eisai Co Ltd announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima® (lenvatinib mesylate) in combination with everolimus...

AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate...

AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate...

Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management. The findings from more than 1,700 rheumatologists* in 15 countries builds upon...

Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. together with an additional investment. As part of the agreement, Otsuka Holdings.   obtained exclusive rights to the commercialization...